Citadel Advisors
JSPR icon

Citadel Advisors’s Jasper Therapeutics JSPR Stock Holding History

Citadel Advisors’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.5K Buy
28,000
+3,000
+12% +$4.16K ﹤0.01% 12625
2025
Q4 		$45.8K Buy
25,000
+7,600
+44% +$15.3K ﹤0.01% 12071
2025
Q3 		$41.4K Sell
17,400
-100
-0.6% -$303 ﹤0.01% 12279
2025
Q2 		$97.1K Sell
17,500
-4,700
-21% -$23.1K ﹤0.01% 11380
2025
Q1 		$95.5K Buy
22,200
+9,400
+73% +$62.6K ﹤0.01% 11543
2024
Q4 		$274K Buy
12,800
+11,200
+700% +$233K ﹤0.01% 9841
2024
Q3 		$30.1K Buy
+1,600
New +$31.9K ﹤0.01% 12437
2024
Q2 		– Sell
-3,800
Closed -$112K – 14882
2024
Q1 		$112K Buy
+3,800
New +$67.5K ﹤0.01% 11201
2023
Q4 		– Sell
-10
Closed -$70 – 14807
2023
Q3 		$70 Sell
10
-30
-75% -$366 ﹤0.01% 14174
2023
Q2 		$548 Sell
40
-330
-89% -$4.9K ﹤0.01% 14091
2023
Q1 		$6.7K Buy
370
+280
+311% +$5.18K ﹤0.01% 13787
2022
Q4 		$428 Buy
+90
New +$602 ﹤0.01% 14659
2022
Q2 		– Sell
-1,360
Closed -$48K – 13513
2022
Q1 		$48K Sell
1,360
-1,970
-59% -$88.8K ﹤0.01% 12816
2021
Q4 		$261K Buy
+3,330
New +$312K ﹤0.01% 11243

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Citadel Advisors's JSPR Position: Q4 2025 in Review

Citadel Advisors sold out of Jasper Therapeutics (JSPR) in Q4 2025, closing a stake of 589,449 shares — an estimated $1.18M sold.

Citadel Advisors first reported a position in JSPR in Q1 2021 and held it in 18 quarters. The position peaked at $29.2M in Q3 2021. 55 funds tracked by Wall St. Rank hold JSPR as of Q4 2025.

  • Citadel Advisors reported no remaining Jasper Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 589,449 Jasper Therapeutics shares in Q4 2025, an estimated $1.18M.
  • Citadel Advisors first reported a position in Jasper Therapeutics in Q1 2021 and held it in 18 quarters.
  • Citadel Advisors's Jasper Therapeutics position peaked at $29.2M in Q3 2021.
  • 55 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.